Prevalencia del síndrome DRESS

López-Rocha, Eunice Giselle; Blancas, Lizbeth; Rodríguez-Mireles, Karen Alicia; Gaspar-López, Arturo; O’Farrill-Romanillos, Patricia María; Amaya-Mejía, Adela Sisy; Galindo-Pacheco, Lucy Vania; Campos-Romero, Freya Helena; Aguilar-Hinojosa, Nadia Karina; Suárez, Guadalupe

doi:10.29262/ram.v61i1.16

Cited by 17 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DRESS syndrome can recur; a systematic review that included 42 articles concluded that the average time to recurrence is 124 days, it usually presents with a higher fever and a higher number of eosinophils, generally attributed to another causal drug. In this study, it is mentioned that the survival of recurrences was 71% [4][5][6].…”

Section: Introductionmentioning

confidence: 72%

DRESS and Stevens–Johnson Syndrome Overlap Secondary to Allopurinol in a 50-Year-Old Man—A Diagnostic and Treatment Challenge: Case Report

Martínez,

Franco,

Sáenz

et al. 2023

Life

View full text Add to dashboard Cite

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a drug reaction commonly related to eosinophilia, from uncertain epidemiology, and without consensus for diagnosis and treatment globally. It presents a great challenge in its management and is characterized by fever, lymphadenopathy, skin rash, and multisystemic involvement. An aggressive and difficult-to-manage clinical case is presented in a 50-year-old man with chronic kidney disease due to diabetes mellitus type 2 and systemic arterial hypertension, who developed an unusual variant similar to DRESS and Stevens–Johnson syndrome (SJS) overlap secondary to allopurinol, with skin manifestations without eosinophilia, but fulfilling clinical and laboratory criteria for DRESS and SJS syndrome.

show abstract

Section: Introductionmentioning

confidence: 72%

DRESS and Stevens–Johnson Syndrome Overlap Secondary to Allopurinol in a 50-Year-Old Man—A Diagnostic and Treatment Challenge: Case Report

Martínez,

Franco,

Sáenz

et al. 2023

Life

View full text Add to dashboard Cite

show abstract

Current Perspectives on Severe Drug Eruption

Zhang

Lei

et al. 2021

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Adverse drug reactions involving the skin are commonly known as drug eruptions. Severe drug eruption may cause severe cutaneous adverse drug reactions (SCARs), which are considered to be fatal and life-threatening, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms (DRESS). Although cases are relatively rare, approximately 2% of hospitalized patients are affected by SCARs. There is an incidence of 2 to 7 cases/million per year of SJS/TEN and 1/1000 to 1/10,000 exposures to offending agents result in DRESS. However, the mortality rate of severe drug eruptions can reach up to 50%. SCARs represent a real medical emergency, and early identification and proper management are critical to survival. The common pathogenesis of severe drug eruptions includes genetic linkage with HLA-and non-HLA-genes, drug-specific T cell-mediated cytotoxicity, T cell receptor restriction, and cytotoxicity mechanisms. A multidisciplinary approach is required for acute management. Immediate withdrawal of potentially causative drugs and specific supportive treatment is of great importance. Immunoglobulins, systemic corticosteroids, and cyclosporine A are the most frequently used treatments for SCARs; additionally, new biologics and plasma exchange are reasonable strategies to reduce mortality. Although there are many treatment methods for severe drug eruption, controversies remain regarding the timing and dosage of drug eruption. Types, dosages, and indications of new biological agents, such as tumor necrosis factor antagonists, mepolizumab, and omalizumab, are still under exploration. This review summarizes the clinical characteristics, risk factors, pathogenesis, and treatment strategies of severe drug eruption to guide clinical management. Keywords Severe drug eruption • Stevens-Johnson syndrome • Toxic epidermal necrolysis • Acute generalized exanthematous pustulosis • Drug reaction with eosinophilia and systemic symptoms Abbreviations AGEP Acute generalized exanthematous pustulosis ALT Alanine aminotransferase APCs Antigen-presenting cells AST Aspartate aminotransferase CBZ Carbamazepine CCR CC-chemokine receptor COVID-19 Coronavirus disease 2019 CTL Cytotoxic T cells CXCR CXC chemokine receptor DiHS

show abstract

Carbamazepine/phenytoin

2014

Reactions Weekly

View full text Add to dashboard Cite

Prevalencia del síndrome DRESS

Cited by 17 publications

References 20 publications

DRESS and Stevens–Johnson Syndrome Overlap Secondary to Allopurinol in a 50-Year-Old Man—A Diagnostic and Treatment Challenge: Case Report

DRESS and Stevens–Johnson Syndrome Overlap Secondary to Allopurinol in a 50-Year-Old Man—A Diagnostic and Treatment Challenge: Case Report

Current Perspectives on Severe Drug Eruption

Carbamazepine/phenytoin

Contact Info

Product

Resources

About